Back to results
US 6,110,697 AGranted
Histone deacetylase as target for antiprotozoal agents
AssigneeMerck & Co., Inc.
InventorsPaula M. Dulski, Robert W. Myers, Anne M. Gumett, Sandra J. Rattray, Dennis M. Schmatz
Life of this patent
Estimating the term…
Abstract
Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.
Claims4
A method for the treatment of protozoal diseases caused by a protozoan belonging to the sub-phylum Apicomplexans comprising administering to a host a therapeutically or prophylactically effective amount of a compound whereby the histone deacetylase of the protozoan is inhibited by said compound.
Dependencies are inferred from the claim text.